CA3175429A1 - Gpr52 modulator compounds - Google Patents
Gpr52 modulator compoundsInfo
- Publication number
- CA3175429A1 CA3175429A1 CA3175429A CA3175429A CA3175429A1 CA 3175429 A1 CA3175429 A1 CA 3175429A1 CA 3175429 A CA3175429 A CA 3175429A CA 3175429 A CA3175429 A CA 3175429A CA 3175429 A1 CA3175429 A1 CA 3175429A1
- Authority
- CA
- Canada
- Prior art keywords
- fluoro
- pyrazole
- trifluoromethyl
- carboxamide
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Amplifiers (AREA)
- Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2003668.7 | 2020-03-13 | ||
| GBGB2003668.7A GB202003668D0 (en) | 2020-03-13 | 2020-03-13 | GPR52 Modulator compounds |
| PCT/GB2021/050638 WO2021181122A1 (en) | 2020-03-13 | 2021-03-15 | Gpr52 modulator compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3175429A1 true CA3175429A1 (en) | 2021-09-16 |
Family
ID=70453676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3175429A Pending CA3175429A1 (en) | 2020-03-13 | 2021-03-15 | Gpr52 modulator compounds |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US12655120B2 (enExample) |
| EP (1) | EP4117784B1 (enExample) |
| JP (1) | JP7492597B2 (enExample) |
| KR (1) | KR20220152296A (enExample) |
| CN (1) | CN115515681B (enExample) |
| AU (1) | AU2021235257B2 (enExample) |
| BR (1) | BR112022018287A2 (enExample) |
| CA (1) | CA3175429A1 (enExample) |
| DK (1) | DK4117784T3 (enExample) |
| ES (1) | ES2992600T3 (enExample) |
| FI (1) | FI4117784T3 (enExample) |
| GB (1) | GB202003668D0 (enExample) |
| HR (1) | HRP20241375T1 (enExample) |
| HU (1) | HUE068758T2 (enExample) |
| IL (1) | IL296413B2 (enExample) |
| LT (1) | LT4117784T (enExample) |
| MX (1) | MX2022011333A (enExample) |
| PL (1) | PL4117784T3 (enExample) |
| PT (1) | PT4117784T (enExample) |
| RS (1) | RS66063B1 (enExample) |
| SI (1) | SI4117784T1 (enExample) |
| SM (1) | SMT202400402T1 (enExample) |
| WO (1) | WO2021181122A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202003668D0 (en) | 2020-03-13 | 2020-04-29 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
| EP4139284A1 (en) | 2020-04-22 | 2023-03-01 | Neurocrine Biosciences, Inc. | Gpr52 modulators and methods of use |
| EP4330232A1 (en) * | 2021-04-26 | 2024-03-06 | Neurocrine Biosciences, Inc. | Gpr52 modulators and methods of use |
| GB202113186D0 (en) | 2021-09-15 | 2021-10-27 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
| WO2024091541A1 (en) * | 2022-10-26 | 2024-05-02 | Neurocrine Biosciences, Inc. | Compounds and compositions as gpr52 modulators |
| WO2024091542A1 (en) * | 2022-10-26 | 2024-05-02 | Neurocrine Biosciences, Inc. | Compounds and compositions as gpr52 modulators |
| AR130864A1 (es) * | 2022-10-26 | 2025-01-29 | Neurocrine Biosciences Inc | Compuestos y composiciones como moduladores de gpr52 |
| WO2025252061A1 (zh) * | 2024-06-04 | 2025-12-11 | 海思科医药集团股份有限公司 | 一种gpr52激动剂及其在医药上的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2327185A1 (en) | 1998-04-08 | 1999-10-14 | Abbott Laboratories | Pyrazole inhibitors of cytokine production |
| US20010044445A1 (en) | 1999-04-08 | 2001-11-22 | Bamaung Nwe Y. | Azole inhibitors of cytokine production |
| NZ526624A (en) | 2000-12-22 | 2005-07-29 | Ortho Mcneil Pharm Inc | Substituted triazole diamine derivatives as kinase inhibitors |
| US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
| WO2005037797A1 (en) * | 2003-10-21 | 2005-04-28 | Pharmacia Corporation | Substituted pyrazole urea compounds for the treatment of inflammation |
| JPWO2009107391A1 (ja) | 2008-02-27 | 2011-06-30 | 武田薬品工業株式会社 | ６員芳香環含有化合物 |
| KR20100097077A (ko) | 2009-02-25 | 2010-09-02 | 주식회사 중외제약 | Ｈｓｐ90에 대한 억제 효능을 갖는 피리디논 유도체 |
| EP2518054A1 (en) | 2009-12-24 | 2012-10-31 | Takeda Pharmaceutical Company Limited | Amide compound |
| EP2530078A1 (en) | 2010-01-27 | 2012-12-05 | Takeda Pharmaceutical Company Limited | Thiazole derivative |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| MX373876B (es) * | 2015-04-29 | 2020-03-26 | Arena Pharm Inc | 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas. |
| WO2017077280A1 (en) | 2015-11-02 | 2017-05-11 | Sonia Lain | Tetrahydroindazoles and medical uses thereof |
| US11279703B2 (en) | 2016-12-01 | 2022-03-22 | Aptose Biosciences Inc. | Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof |
| CN111094278B (zh) | 2017-09-13 | 2023-07-14 | 诺华股份有限公司 | 二苯基衍生物及其用途 |
| JP7425724B2 (ja) | 2017-10-17 | 2024-01-31 | エピザイム，インコーポレイティド | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体 |
| AU2018353150B2 (en) | 2017-10-18 | 2024-06-06 | Epizyme, Inc. | Methods of using EHMT2 inhibitors in treating or preventing blood disorders |
| US20210213014A1 (en) | 2017-10-18 | 2021-07-15 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in immunotherapies |
| CN114650992A (zh) | 2019-11-08 | 2022-06-21 | 赫普泰雅治疗有限公司 | Gpr52调节剂化合物 |
| GB202003668D0 (en) | 2020-03-13 | 2020-04-29 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
| GB202013558D0 (en) | 2020-08-28 | 2020-10-14 | Heptares Therapeutics Ltd | GRP52 Modularor compounds |
-
2020
- 2020-03-13 GB GBGB2003668.7A patent/GB202003668D0/en not_active Ceased
-
2021
- 2021-03-15 ES ES21713103T patent/ES2992600T3/es active Active
- 2021-03-15 IL IL296413A patent/IL296413B2/en unknown
- 2021-03-15 KR KR1020227035100A patent/KR20220152296A/ko active Pending
- 2021-03-15 WO PCT/GB2021/050638 patent/WO2021181122A1/en not_active Ceased
- 2021-03-15 MX MX2022011333A patent/MX2022011333A/es unknown
- 2021-03-15 LT LTEPPCT/GB2021/050638T patent/LT4117784T/lt unknown
- 2021-03-15 AU AU2021235257A patent/AU2021235257B2/en active Active
- 2021-03-15 HU HUE21713103A patent/HUE068758T2/hu unknown
- 2021-03-15 SI SI202130212T patent/SI4117784T1/sl unknown
- 2021-03-15 PL PL21713103.6T patent/PL4117784T3/pl unknown
- 2021-03-15 HR HRP20241375TT patent/HRP20241375T1/hr unknown
- 2021-03-15 RS RS20241089A patent/RS66063B1/sr unknown
- 2021-03-15 DK DK21713103.6T patent/DK4117784T3/da active
- 2021-03-15 EP EP21713103.6A patent/EP4117784B1/en active Active
- 2021-03-15 JP JP2022555137A patent/JP7492597B2/ja active Active
- 2021-03-15 BR BR112022018287A patent/BR112022018287A2/pt unknown
- 2021-03-15 US US17/909,792 patent/US12655120B2/en active Active
- 2021-03-15 FI FIEP21713103.6T patent/FI4117784T3/fi active
- 2021-03-15 PT PT217131036T patent/PT4117784T/pt unknown
- 2021-03-15 CN CN202180033813.9A patent/CN115515681B/zh active Active
- 2021-03-15 SM SM20240402T patent/SMT202400402T1/it unknown
- 2021-03-15 CA CA3175429A patent/CA3175429A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL296413B1 (en) | 2025-11-01 |
| KR20220152296A (ko) | 2022-11-15 |
| HUE068758T2 (hu) | 2025-01-28 |
| IL296413A (en) | 2022-11-01 |
| HRP20241375T1 (hr) | 2024-12-20 |
| FI4117784T3 (fi) | 2024-10-10 |
| PL4117784T3 (pl) | 2025-01-13 |
| JP2023519666A (ja) | 2023-05-12 |
| IL296413B2 (en) | 2026-03-01 |
| SMT202400402T1 (it) | 2024-11-15 |
| WO2021181122A1 (en) | 2021-09-16 |
| DK4117784T3 (da) | 2024-10-14 |
| BR112022018287A2 (pt) | 2022-11-22 |
| MX2022011333A (es) | 2022-12-08 |
| JP7492597B2 (ja) | 2024-05-29 |
| GB202003668D0 (en) | 2020-04-29 |
| US12655120B2 (en) | 2026-06-16 |
| AU2021235257A1 (en) | 2022-10-06 |
| CN115515681A (zh) | 2022-12-23 |
| PT4117784T (pt) | 2024-10-07 |
| LT4117784T (lt) | 2024-10-25 |
| EP4117784B1 (en) | 2024-08-28 |
| AU2021235257B2 (en) | 2026-07-16 |
| ES2992600T3 (en) | 2024-12-16 |
| SI4117784T1 (sl) | 2025-03-31 |
| RS66063B1 (sr) | 2024-11-29 |
| US20240254101A1 (en) | 2024-08-01 |
| EP4117784A1 (en) | 2023-01-18 |
| CN115515681B (zh) | 2024-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4117784B1 (en) | Gpr52 modulator compounds | |
| CA2672521C (en) | Pyrazole derivatives as protein kinase inhibitors | |
| US8314094B2 (en) | Benzoxazinone derivative | |
| KR101014525B1 (ko) | 신규 화합물 | |
| ES2460915T3 (es) | Piridinas fusionadas con heteroarilo disustituido | |
| EP1835934A2 (en) | Enzyme modulators and treatments | |
| WO2003031435A1 (en) | Pyrazole derivatives as glycine transporter inhibitors | |
| RS55750B1 (sr) | Jedinjenja pirazola kao inhibitori sigma receptora | |
| AU2013275209A1 (en) | Branched chain alkyl heteroaromatic ring derivative | |
| WO2009006389A2 (en) | Pyrimidine derivatives useful as raf kinase inhibitors | |
| WO2018192866A1 (en) | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | |
| KR20130143141A (ko) | 피라졸리딘-3-온 유도체 | |
| JP2016510810A (ja) | オレキシン受容体アンタゴニストとしてのアゼチジンアミド誘導体 | |
| CN116888115A (zh) | 二氟甲基-吡啶-2-基三唑 | |
| CA3232606A1 (en) | Gpr52 modulator compounds | |
| RU2844473C1 (ru) | Соединения модуляторы gpr52 | |
| HK40078521A (en) | Gpr52 modulator compounds | |
| HK40078521B (en) | Gpr52 modulator compounds | |
| HK40107480A (en) | Gpr52 modulator compounds | |
| HK40107480B (en) | Gpr52 modulator compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED Effective date: 20240726 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241023 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241125 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241209 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241209 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241209 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250129 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250129 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250129 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250218 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250228 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250305 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250612 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250725 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250725 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250725 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250725 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251202 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251202 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260309 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260324 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260513 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260702 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260707 |